Control (C) for Cardiac Diseases

Phase-Based Progress Estimates
Cardiac Diseases+1 More
Control - Behavioral
Any Age
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new model for delivering group exercise training for people with heart disease. The model includes live-streaming of CR exercise classes. Two versions of these classes are available: one that does not require any exercise equipment; and one that relies on a stationary exercise bike and exercise band delivered and installed in patients' homes.

Eligible Conditions
  • Cardiac Diseases

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

4 Primary · 0 Secondary · Reporting Duration: 8 weeks

8 weeks
Feasibility of equipment delivery
Feasibility of recruitment

Trial Safety

Trial Design

3 Treatment Groups

Control (C)
1 of 3
Exercise Streaming (ES)
1 of 3
Exercise Streaming + Equipment (ES+E)
1 of 3

Active Control

36 Total Participants · 3 Treatment Groups

Primary Treatment: Control (C) · No Placebo Group · N/A

Control (C)
ActiveComparator Group · 1 Intervention: Control · Intervention Types: Behavioral
Exercise Streaming (ES)
ActiveComparator Group · 1 Intervention: Exercise Streaming (ES) · Intervention Types: Behavioral
Exercise Streaming + Equipment (ES+E)
ActiveComparator Group · 1 Intervention: Exercise Streaming + Equipment (ES+E) · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 8 weeks

Who is running the clinical trial?

Ottawa Heart Institute Research CorporationLead Sponsor
179 Previous Clinical Trials
88,154 Total Patients Enrolled
Thais Coutinho, MDPrincipal InvestigatorOttawa Heart Institute Research Corporation
1 Previous Clinical Trials
25 Total Patients Enrolled

Eligibility Criteria

Age Any Age · All Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 30th, 2021

Last Reviewed: November 27th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.